Table 4

Cost (£ per patient) and cost-effectiveness results

ParameterMain model*Alternative model*
BivalirudinH-GPIΔBivalirudinH-GPIΔ
Cost of bivalirudin37003703700370
Cost of GPI42573−53142573−531
Ward cost (initial hospitalisation)20642259−19520642259−195
Procedure and clinical event cost during year 1/years 1–324842509−2529032939−36
Cardiovascular outpatient treatment and drug cost in year 1/years 1–3876864122508247038
Total cost in year 1/years 1–358376204−36778868241−355
Long-term cardiovascular treatment cost after year 1 or year 37006690610055935489104
Total cost12 84313 110−26713 48013 730−250
QALYs per patient6.266.170.096.436.320.11
ICER (£ per QALY gained)Bivalirudin strategy dominant§Bivalirudin strategy dominant§
  • * In the main model, detailed modelling of clinical events covered the first year after the initial STEMI event. In the alternative model, this time period was extended to 3 years.

  • Excluding initial hospitalisation ward costs.

  • Discounted at 3.5% per year, starting in year 2.

  • § If one strategy dominates the alternative—that is, if it is more clinically effective and less costly, calculating an ICER is numerically possible but the result has no meaningful interpretation. Differences in effectiveness and cost are therefore shown side-by-side.

  • Δ, difference; GPI, glycoprotein IIb/IIIa inhibitor; H-GPI, heparin and glycoprotein IIb/IIIa inhibitor; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.